196 related articles for article (PubMed ID: 20038957)
1. A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
Deeken JF; Cormier T; Price DK; Sissung TM; Steinberg SM; Tran K; Liewehr DJ; Dahut WL; Miao X; Figg WD
Pharmacogenomics J; 2010 Jun; 10(3):191-9. PubMed ID: 20038957
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Sissung TM; Baum CE; Deeken J; Price DK; Aragon-Ching J; Steinberg SM; Dahut W; Sparreboom A; Figg WD
Clin Cancer Res; 2008 Jul; 14(14):4543-9. PubMed ID: 18628469
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries.
Awada Z; Haider S; Tfayli A; Bazarbachi A; El-Saghir NS; Salem Z; Shamseddine A; Taher A; Zgheib NK
OMICS; 2013 Jul; 17(7):353-67. PubMed ID: 23758476
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
Sissung TM; Danesi R; Kirkland CT; Baum CE; Ockers SB; Stein EV; Venzon D; Price DK; Figg WD
J Clin Endocrinol Metab; 2011 Feb; 96(2):E368-72. PubMed ID: 21106711
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Ning YM; Gulley JL; Arlen PM; Woo S; Steinberg SM; Wright JJ; Parnes HL; Trepel JB; Lee MJ; Kim YS; Sun H; Madan RA; Latham L; Jones E; Chen CC; Figg WD; Dahut WL
J Clin Oncol; 2010 Apr; 28(12):2070-6. PubMed ID: 20308663
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
7. Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC; Sandanaraj E; Singh O; Chen X; Tan EH; Lim WT; Lee EJ; Chowbay B
Br J Clin Pharmacol; 2012 Apr; 73(4):606-18. PubMed ID: 21995462
[TBL] [Abstract][Full Text] [Related]
8. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Horne MK; Figg WD; Arlen P; Gulley J; Parker C; Lakhani N; Parnes H; Dahut WL
Pharmacotherapy; 2003 Mar; 23(3):315-8. PubMed ID: 12627929
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Figg WD; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger EA; Pluda J; Dahut WL
Semin Oncol; 2001 Aug; 28(4 Suppl 15):62-6. PubMed ID: 11685731
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Chen S; Sutiman N; Zhang CZ; Yu Y; Lam S; Khor CC; Chowbay B
Drug Metab Rev; 2016 Nov; 48(4):502-540. PubMed ID: 27546072
[TBL] [Abstract][Full Text] [Related]
11. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
Di Martino MT; Arbitrio M; Leone E; Guzzi PH; Rotundo MS; Ciliberto D; Tomaino V; Fabiani F; Talarico D; Sperlongano P; Doldo P; Cannataro M; Caraglia M; Tassone P; Tagliaferri P
Cancer Biol Ther; 2011 Nov; 12(9):780-7. PubMed ID: 21892003
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
Frederiks CN; Lam SW; Guchelaar HJ; Boven E
Cancer Treat Rev; 2015 Dec; 41(10):935-50. PubMed ID: 26585358
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.
Di Lorenzo G; Autorino R; De Laurentiis M; Forestieri V; Romano C; Prudente A; Giugliano F; Imbimbo C; Mirone V; De Placido S
Cancer Biol Ther; 2007 Mar; 6(3):313-7. PubMed ID: 17327701
[TBL] [Abstract][Full Text] [Related]
14. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Kellokumpu-Lehtinen PL; Harmenberg U; Joensuu T; McDermott R; Hervonen P; Ginman C; Luukkaa M; Nyandoto P; Hemminki A; Nilsson S; McCaffrey J; Asola R; Turpeenniemi-Hujanen T; Laestadius F; Tasmuth T; Sandberg K; Keane M; Lehtinen I; Luukkaala T; Joensuu H;
Lancet Oncol; 2013 Feb; 14(2):117-24. PubMed ID: 23294853
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
Figg WD; Li H; Sissung T; Retter A; Wu S; Gulley JL; Arlen P; Wright JJ; Parnes H; Fedenko K; Latham L; Steinberg SM; Jones E; Chen C; Dahut W
BJU Int; 2007 May; 99(5):1047-55. PubMed ID: 17437439
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
[TBL] [Abstract][Full Text] [Related]
17. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
Trump DL; Payne H; Miller K; de Bono JS; Stephenson J; Burris HA; Nathan F; Taboada M; Morris T; Hubner A
Prostate; 2011 Sep; 71(12):1264-75. PubMed ID: 21271613
[TBL] [Abstract][Full Text] [Related]
18. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
Li H; Raia V; Bertolini F; Price DK; Figg WD
BJU Int; 2008 Apr; 101(7):884-8. PubMed ID: 18070197
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.
Behrens RJ; Gulley JL; Dahut WL
Am J Ther; 2003; 10(3):228-32. PubMed ID: 12756431
[TBL] [Abstract][Full Text] [Related]
20. Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.
Franke RM; Carducci MA; Rudek MA; Baker SD; Sparreboom A
J Clin Oncol; 2010 Oct; 28(30):4562-7. PubMed ID: 20855838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
